Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.41 |
| ▸ | HTR3B | O95264 | 3/20 | 0.41 |
| ▸ | HTR3A | P46098 | 3/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | HTR5A | P47898 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL657213 | 0.84 | HRH3 (0.49) | HRH3ADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL8259619 | 0.81 | ADRB1 (0.43) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL659276 | 0.80 | ALDH1A1 (0.40) | HRH3ADRB1HTR3EHTR3BHTR3A | |
| SCHEMBL8256379 | 0.78 | ADRB1 (0.44) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL15304718 | 0.76 | ADRB1 (0.40) | ADRB1HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL8251627 | 0.74 | HRH3 (0.44) | HRH3HRH4 | |
| SCHEMBL14367885 | 0.74 | HRH3 (0.44) | HRH3HRH4 | |
| SCHEMBL9983626 | 0.73 | HRH3 (0.43) | HRH3ADRB1HTR1AHRH4 | |
| SCHEMBL8250882 | 0.73 | HRH3 (0.43) | HRH3HRH4 | |
| SCHEMBL8282287 | 0.73 | HRH3 (0.43) | HRH3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046277-A1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-23 | — | — | US | claimed |
| EP-2406243-A1 | BENZOFURAN DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2012-01-18 | — | — | EP | claimed |
| WO-2010104194-A1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | WO | claimed |
| US-20100234357-A1 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | claimed |
| US-8957069-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-17 | — | — | US | disclosed |
| EP-2781513-A1 | Benzofuran derivatives | Takeda Pharmaceutical Company Limited (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-8288390-B2 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120232095-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232096-A1 | BENZOFURAN DERIVATIVES | TSUKAMOTO TETSUYA (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120046277-A1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
| EP-2406243-A1 | BENZOFURAN DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010104194-A1 | BENZOFURAN DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | WO | disclosed |
| US-20100234357-A1 | Benzofuran derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| US-7709492-B2 | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709492-B2 | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1622912-B1 | 2-ALKYNYL-AND 2-ALKENYL-PYRAZOLO- [4,3-E ] -1,2,4-TRIAZOLO- [1,5-C] -PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7368449-B2 | 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368449-B2 | 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232096-A1 | BENZOFURAN DERIVATIVES | AHR, BRPF3, CBR3 | HRH3 118/4885ADRB1 294/4885HTR3E 606/4885 |
| US-20100234357-A1 | Benzofuran derivatives | AHR, BRPF3, CBR3 | HRH3 118/4885ADRB1 294/4885HTR3E 606/4885 |
| US-20120232095-A1 | BENZOFURAN DERIVATIVES | AHR, BRPF3, CBR3 | HRH3 118/4885ADRB1 294/4885HTR3E 606/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | HRH3 60/4885ADRB1 34/4885HTR3E 40/4885 |
| US-20120046277-A1 | BENZOFURAN DERIVATIVES | BRPF3, BRD1, CBR3 | HRH3 286/4885ADRB1 241/4885HTR3E 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.